{
    "symbol": "ACAD",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-08 21:05:04",
    "content": " Our business plan is focused on following priorities: maximize the value of our Parkinson's disease franchise with NUPLAZID, deliver trofinetide to market is our second commercial product and the first FDA-approved treatment for Rett syndrome, complete our second pivotal study in symptoms of schizophrenia, disciplined early-stage development to selectively advance molecules into late-stage development; and finally, positioning ourselves to leverage an increasingly attractive opportunity set in business development, by carefully allocating capital as we fund our current business from our existing balance sheet and move to cash flow positive."
}